A Clinical Study of IL13Rα2 Targeted CAR-T in Patients With Malignant Glioma (MAGIC-I)
NCT05540873
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
18
Enrollment
INDUSTRY
Sponsor class
Conditions
Recurrent Malignant Glioma
Interventions
DRUG:
YYB-103
Sponsor
CellabMED